Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy

Journal of Clinical Immunology

Volumn 29, Issue 5, 2009, Pages 657-664

  Cornforth, Andrew N ^a   Lee, Gregory J ^a   Fowler, Abner W ^a   Carbonell, Denysha J ^a   Dillman, Robert O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Chemokine; Cytoarray; Dendritic cell; ELISA; Melanoma; Vaccine

Indexed keywords

ANGIOGENIN; CHEMOKINE; COLONY STIMULATING FACTOR 1; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; ONCOSTATIN M; PLATELET DERIVED GROWTH FACTOR BB; RANTES; SOMATOMEDIN C; STEM CELL FACTOR; THROMBOPOIETIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHEMOKINE CCL17; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RIBONUCLEASE, PANCREATIC;

EID: 69249217796     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-009-9299-3     Document Type: Article

References (31)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010
2. E Gilboa 2007 DC-based cancer vaccines J Clin Invest 117 1195 1203 10.1172/JCI31205 (Pubitemid 46718404)
3. AK Palucka H Ueno JW Fay J Banchereau 2007 Taming cancer by inducing immunity via dendritic cells Immunol Rev 220 129 150 10.1111/j.1600-065X.2007. 00575.x (Pubitemid 350045575)
4. EH Aarntzen CG Figdor GJ Adema CJ Punt IJ de Vries 2008 Dendritic cell vaccination and immune monitoring Cancer Immunol Immunother 57 1559 1568 10.1007/s00262-008-0553-y
5. M Feili-Hariri DH Falkner PA Morel 2005 Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy J Leukoc Biol 78 656 664 10.1189/jlb.1104631 (Pubitemid 41292088)
6. JL Vissers FC Hartgers E Lindhout MB Teunissen CG Figdor GJ Adema 2001 Quantitative analysis of chemokine expression by dendritic cell subsets in vitro and in vivo J Leukoc Biol 69 785 793 (Pubitemid 32466418)
7. D Nagorsen FM Marincola MC Panelli 2004 Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays Cytokine 25 31 35 10.1016/j.cyto.2003.08.012 (Pubitemid 37543695)
8. S Ugurel G Rappl W Tilgen U Reinhold 2001 Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival J Clin Oncol 19 577 583
9. S Brennecke M Deichmann H Naeher H Kurzen 2005 Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma Melanoma Res 15 515 522 10.1097/00008390-200512000-00006 (Pubitemid 44124263)
10. P Vihinen M Kallioinen MS Vuoristo J Ivaska KJ Syrjanen M Hahka-Kemppinen, et al. 2007 Serum angiogenin levels predict treatment response in patients with stage IV melanoma Clin Exp Metastasis 24 567 574 10.1007/s10585-007-9093-7 (Pubitemid 47524814)
11. EA Grimm CM Smid JJ Lee CH Tseng O Eton AC Buzaid 2000 Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy Clin Cancer Res 6 3895 3903
12. D Choi M Perrin S Hoffmann AE Chang V Ratanatharathorn J Uberti, et al. 1998 Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34 + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells Clin Cancer Res 4 2709 2716
13. T Luft KC Pang E Thomas CJ Bradley H Savoia J Trapani, et al. 1998 A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells Exp Hematol 26 489 500
14. RO Dillman SK Nayak L Beutel 1993 Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy J Immunother Emphasis Tumor Immunol 14 65 69
15. RO Dillman LD Beutel AN Cornforth SK Nayak 2000 Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer Cancer Biother Radiopharm 15 161 168 10.1089/cbr.2000.15.161
16. SR Selvan RO Dillman AW Fowler DJ Carbonell MH Ravindranath 2008 Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker Int J Cancer 122 6 1374 1383
17. RO Dillman LD Beutel NM Barth C de Leon AA O'Connor C DePriest, et al. 2002 Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival Cancer Biother Radiopharm 17 51 66 10.1089/10849780252824073
18. SS Shapiro M Wilk 1965 An analysis of variance test for normality (complete samples) Biometrika 52 591 611
19. JA Hanley BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 29 36
20. ZR Yurkovetsky JM Kirkwood HD Edington AM Marrangoni L Velikokhatnaya MT Winans, et al. 2007 Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b Clin Cancer Res 13 2422 2428 10.1158/1078-0432.CCR-06-1805 (Pubitemid 46698593)
21. RO Dillman SR Selvan PM Schiltz 2006 Patient-specific dendritic-cell vaccines for metastatic melanoma N Engl J Med 355 1179 1181 10.1056/NEJMc061667
22. A Zlotnik 2006 Chemokines and cancer Int J Cancer 119 2026 2029 10.1002/ijc.22024 (Pubitemid 44423657)
23. Z Guo M Zhang H Tang X Cao 2005 Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines Blood 106 2033 2041 10.1182/blood-2004-12-4831 (Pubitemid 41291717)
24. MC Lebre T Burwell PL Vieira J Lora AJ Coyle ML Kapsenberg, et al. 2005 Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation Immunol Cell Biol 83 525 535 10.1111/j.1440-1711.2005.01365.x (Pubitemid 41805755)
25. IJ de Vries AA Eggert NM Scharenborg JL Vissers WJ Lesterhuis OC Boerman, et al. 2002 Phenotypical and functional characterization of clinical grade dendritic cells J Immunother 25 429 438
26. N Kanagawa M Niwa Y Hatanaka Y Tani S Nakagawa T Fujita, et al. 2007 CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma Int J Cancer 121 2013 2022 10.1002/ijc.22908 (Pubitemid 47463165)
27. N Okada A Sasaki M Niwa Y Okada Y Hatanaka Y Tani, et al. 2006 Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector Cancer Gene Ther 13 393 405 10.1038/sj.cgt.7700903
28. Y Nakazaki H Hase H Inoue Y Beppu XK Meng G Sakaguchi, et al. 2006 Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses Mol Ther 14 599 606 10.1016/j.ymthe.2006.04.014 (Pubitemid 44296094)
29. H Inoue M Iga M Xin S Asahi T Nakamura R Kurita, et al. 2008 TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model Cancer Immunol Immunother 57 1399 1411 10.1007/s00262-008-0476-7
30. T Imai M Nagira S Takagi M Kakizaki M Nishimura J Wang, et al. 1999 Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine Int Immunol 11 81 88 10.1093/intimm/11.1.81 (Pubitemid 29037591)
31. N Mach S Gillessen SB Wilson C Sheehan M Mihm G Dranoff 2000 Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand Cancer Res 60 3239 3246